Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04544449




Registration number
NCT04544449
Ethics application status
Date submitted
4/09/2020
Date registered
10/09/2020
Date last updated
3/05/2024

Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
Scientific title
A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Patients With Primary Progressive Multiple Sclerosis.
Secondary ID [1] 0 0
2019-003919-53
Secondary ID [2] 0 0
GN41791
Universal Trial Number (UTN)
Trial acronym
FENtrepid
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Sclerosis, Primary Progressive 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Fenebrutinib
Treatment: Drugs - Ocrelizumab
Treatment: Drugs - Placebo matched to ocrelizumab
Treatment: Drugs - Placebo matched to fenebrutinib

Experimental: Fenebrutinib - Participants will receive oral fenebrutinib and intravenous (IV) ocrelizumab-matching placebo.

Active Comparator: Ocrelizumab - Participants will receive intravenous (IV) ocrelizumab and oral fenebrutinib-matching placebo.


Treatment: Drugs: Fenebrutinib
Participants will receive fenebrutinib.

Treatment: Drugs: Ocrelizumab
Participants will receive ocrelizumab.

Treatment: Drugs: Placebo matched to ocrelizumab
Participants will receive ocrelizumab-matching placebo.

Treatment: Drugs: Placebo matched to fenebrutinib
Participants will receive fenebrutinib-matching placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to Onset of Composite 12-week Confirmed Disability Progression (cCDP12)
Timepoint [1] 0 0
Minimum of 120 weeks
Secondary outcome [1] 0 0
Time to Onset of Composite 24-week CDP (cCDP24)
Timepoint [1] 0 0
Minimum of 120 weeks
Secondary outcome [2] 0 0
Time to Onset of 12-week CDP (CDP12)
Timepoint [2] 0 0
Minimum of 120 weeks
Secondary outcome [3] 0 0
Time to Onset of 24-week CDP (CDP24)
Timepoint [3] 0 0
Minimum of 120 weeks
Secondary outcome [4] 0 0
Percentage Change in Total Brain Volume Assessed by Magnetic Resonance Imaging (MRI)
Timepoint [4] 0 0
From Week 24 to Week 120
Secondary outcome [5] 0 0
Change from Baseline in Participant-Reported Physical Impacts of Multiple Sclerosis (MS) Measured by the Multiple Sclerosis Impact Scale, 29-Item [MSIS-29] Physical Scale
Timepoint [5] 0 0
Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120
Secondary outcome [6] 0 0
Time to Onset of 12-week Confirmed 4-point Worsening in Symbol Digit Modality Test (SDMT) Score
Timepoint [6] 0 0
Minimum of 120 weeks
Secondary outcome [7] 0 0
Percentage of Participants with Adverse Events (AEs)
Timepoint [7] 0 0
Up to 4.7 years
Secondary outcome [8] 0 0
Plasma Concentrations of Fenebrutinib at Specified Timepoints
Timepoint [8] 0 0
Up to 4.7 years
Secondary outcome [9] 0 0
Percent Change from Screening in Serum Neurofilament Light Chain (NfL) Levels
Timepoint [9] 0 0
Up to Week 120

Eligibility
Key inclusion criteria
- For sites in Germany and Italy only, enrollment is restricted to participants aged
46-65 years

- A diagnosis of PPMS in accordance to the revised 2017 McDonald Criteria (Thompson et
al. 2018).

- Disability progression in the 12 months prior to screening.

- Expanded Disability Status Scale (EDSS) score from 3.0 to 6.5 inclusive at screening.

- Pyramidal functional subscore >=2 at screening.

- For participants currently receiving proton pump inhibitors (PPIs), H2-receptor
antagonists (H2RAs), symptomatic treatment for MS (e.g. fampridine, cannabis) and/or
physiotherapy: treatment at a stable dose during the screening period prior to the
initiation of study treatment and plans to remain at a stable dose for the duration of
study treatment.

- Neurologically stable for at least 30 days prior to randomization and baseline
assessments.

- Ability to complete the 9-Hole Peg Test (9-HPT) for each hand in <240 seconds.

- Ability to perform Timed 25-Foot Walk Test (T25FWT) in <150 seconds.

- For female participants of childbearing potential: agreement to remain abstinent
(refrain from heterosexual intercourse) or use contraceptive measures, and refrain
from donating eggs.

- For male participants: agreement to remain abstinent (refrain from heterosexual
intercourse) or use contraceptive measures, and refrain from donating sperm.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- For participants enrolled in Germany and in Italy only: Presence of
gadolinium-enhancing lesions on T1-weighted MRI (T1Gd +) lesion on the screening MRI

- Any known or suspected active infection (excluding onychomycosis) at screening,
including but not limited to a positive screening test for Hepatitis B and C, an
active or latent or inadequately treated infection with tuberculosis (TB), a confirmed
or suspected progressive multifocal leukoencephalopathy (PML).

- Participants with a previous history of a serious Infusion-Related Reaction (IRR)
(Common Terminology Criteria for Adverse Events [CTCAE] Grade >= 4) and/or any
hypersensitivity reaction to ocrelizumab.

- History of cancer including hematologic malignancy and solid tumors within 10 years of
screening. Exceptions: Basal/squamous cell carcinoma of skin cured by excision. In
situ carcinoma of the cervix successfully treated by curative therapy >1 year prior to
screening.

- Known presence of other neurological disorders, that could interfere with the
diagnosis of MS or assessments of efficacy or safety during the study, clinically
significant cardiovascular, psychiatric, pulmonary, renal, hepatic, endocrine,
metabolic or gastrointestinal disease.

- Presence of cirrhosis (Child-Pugh Class A, B, or C)

- Any concomitant disease that may require chronic treatment with systemic
corticosteroids, immunosuppressants or specific medication that could impact the
primary evaluation of the study.

- History of alcohol or other drug abuse within 12 months prior to screening.

- Female participants who are pregnant or breastfeeding or intending to become pregnant
during the study or 6 or 12 months (as applicable from the local label for
ocrelizumab) after final dose of study drug.

- Male participants intending to father a child during the study or for 28 days after
final dose of study drug.

- Lack of peripheral venous access.

- Any previous treatment with immunomodulatory or immunosuppressive medication without
an appropriate washout period.

- Receipt of a live or live-attenuated vaccine within 6 weeks prior to randomization.

- Immunocompromised state, history of primary or secondary (non-drug related)
immunodeficiency, or history of transplantation or antirejection therapy

- Known bleeding diathesis, anemia, or history of hospitalization or transfusion for
gastrointestinal (GI) bleed

- Any previous treatment with cladribine, mitoxantrone, daclizumab, alemtuzumab, or
cyclophosphamide

OLE Inclusion Criteria:

- Completed the Double-Blind Treatment (DBT) phase of the study (remaining on study
treatment; no other Disease-Modifying Therapy (DMT) administered) and who, in the
opinion of the investigator, may benefit from treatment with fenebrutinib.

- For female participants of childbearing potential: agreement to remain abstinent
(refrain from heterosexual intercourse) or use contraceptive measures, and refrain
from donating eggs.

- For male participants: agreement to remain abstinent (refrain from heterosexual
intercourse) or use contraceptive measures, and refrain from donating sperm.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/10/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
18/12/2026
Actual
Sample size
Target
Accrual to date
Final
985
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Brain and Mind Research Institute - Camperdown
Recruitment hospital [2] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [3] 0 0
John Hunter Hospital - New Lambton
Recruitment hospital [4] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [5] 0 0
Box Hill Hospital; Department of Neurology - Box Hill
Recruitment hospital [6] 0 0
Austin Hospital; Department of Neurology - Heidelberg
Recruitment hospital [7] 0 0
Royal Melbourne Hospital; Department of Neurology - Parkville
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2170 - Liverpool
Recruitment postcode(s) [3] 0 0
2305 - New Lambton
Recruitment postcode(s) [4] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [5] 0 0
3128 - Box Hill
Recruitment postcode(s) [6] 0 0
3084 - Heidelberg
Recruitment postcode(s) [7] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Nevada
Country [15] 0 0
United States of America
State/province [15] 0 0
New Jersey
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oregon
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Washington
Country [23] 0 0
United States of America
State/province [23] 0 0
West Virginia
Country [24] 0 0
United States of America
State/province [24] 0 0
Wisconsin
Country [25] 0 0
Argentina
State/province [25] 0 0
Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Caba
Country [27] 0 0
Argentina
State/province [27] 0 0
Ciudad Autonoma de Buenos Aires
Country [28] 0 0
Argentina
State/province [28] 0 0
Cordoba
Country [29] 0 0
Argentina
State/province [29] 0 0
Rosario
Country [30] 0 0
Argentina
State/province [30] 0 0
San Miguel
Country [31] 0 0
Austria
State/province [31] 0 0
Linz
Country [32] 0 0
Austria
State/province [32] 0 0
Wien
Country [33] 0 0
Brazil
State/province [33] 0 0
MG
Country [34] 0 0
Brazil
State/province [34] 0 0
PR
Country [35] 0 0
Brazil
State/province [35] 0 0
RJ
Country [36] 0 0
Brazil
State/province [36] 0 0
RS
Country [37] 0 0
Brazil
State/province [37] 0 0
SC
Country [38] 0 0
Brazil
State/province [38] 0 0
SP
Country [39] 0 0
Bulgaria
State/province [39] 0 0
Pleven
Country [40] 0 0
Bulgaria
State/province [40] 0 0
Sofia
Country [41] 0 0
Canada
State/province [41] 0 0
Alberta
Country [42] 0 0
Canada
State/province [42] 0 0
British Columbia
Country [43] 0 0
Canada
State/province [43] 0 0
New Brunswick
Country [44] 0 0
Canada
State/province [44] 0 0
Ontario
Country [45] 0 0
Canada
State/province [45] 0 0
Quebec
Country [46] 0 0
Chile
State/province [46] 0 0
Santiago
Country [47] 0 0
Chile
State/province [47] 0 0
Vitacura
Country [48] 0 0
Colombia
State/province [48] 0 0
Bogota, D.C.
Country [49] 0 0
Colombia
State/province [49] 0 0
Cali
Country [50] 0 0
Colombia
State/province [50] 0 0
Medellin
Country [51] 0 0
Denmark
State/province [51] 0 0
Aarhus N
Country [52] 0 0
Denmark
State/province [52] 0 0
Glostrup
Country [53] 0 0
France
State/province [53] 0 0
Bordeaux
Country [54] 0 0
France
State/province [54] 0 0
Bron
Country [55] 0 0
France
State/province [55] 0 0
Montpellier
Country [56] 0 0
France
State/province [56] 0 0
Nantes
Country [57] 0 0
France
State/province [57] 0 0
Nice
Country [58] 0 0
France
State/province [58] 0 0
Strasbourg
Country [59] 0 0
Germany
State/province [59] 0 0
Berlin
Country [60] 0 0
Germany
State/province [60] 0 0
Böblingen
Country [61] 0 0
Germany
State/province [61] 0 0
Dresden
Country [62] 0 0
Germany
State/province [62] 0 0
Freiburg
Country [63] 0 0
Germany
State/province [63] 0 0
München
Country [64] 0 0
Germany
State/province [64] 0 0
Tuebingen
Country [65] 0 0
Germany
State/province [65] 0 0
Wiesbaden
Country [66] 0 0
Greece
State/province [66] 0 0
Athens
Country [67] 0 0
Greece
State/province [67] 0 0
Thessaloniki
Country [68] 0 0
Hungary
State/province [68] 0 0
Budapest
Country [69] 0 0
Hungary
State/province [69] 0 0
Eger
Country [70] 0 0
Hungary
State/province [70] 0 0
Kistarcsa
Country [71] 0 0
Israel
State/province [71] 0 0
Haifa
Country [72] 0 0
Israel
State/province [72] 0 0
Ramat-Gan
Country [73] 0 0
Israel
State/province [73] 0 0
Tel Aviv
Country [74] 0 0
Italy
State/province [74] 0 0
Campania
Country [75] 0 0
Italy
State/province [75] 0 0
Emilia-Romagna
Country [76] 0 0
Italy
State/province [76] 0 0
Lazio
Country [77] 0 0
Italy
State/province [77] 0 0
Liguria
Country [78] 0 0
Italy
State/province [78] 0 0
Lombardia
Country [79] 0 0
Italy
State/province [79] 0 0
Molise
Country [80] 0 0
Italy
State/province [80] 0 0
Sicilia
Country [81] 0 0
Mexico
State/province [81] 0 0
Mexico CITY (federal District)
Country [82] 0 0
North Macedonia
State/province [82] 0 0
Skopje
Country [83] 0 0
Peru
State/province [83] 0 0
Bellavista
Country [84] 0 0
Peru
State/province [84] 0 0
Lima
Country [85] 0 0
Poland
State/province [85] 0 0
Bydgoszcz
Country [86] 0 0
Poland
State/province [86] 0 0
Katowice
Country [87] 0 0
Poland
State/province [87] 0 0
Lodz
Country [88] 0 0
Poland
State/province [88] 0 0
Pozna?
Country [89] 0 0
Poland
State/province [89] 0 0
Rzeszow
Country [90] 0 0
Poland
State/province [90] 0 0
Rzeszów
Country [91] 0 0
Poland
State/province [91] 0 0
Warszawa
Country [92] 0 0
Poland
State/province [92] 0 0
Wroc?aw
Country [93] 0 0
Poland
State/province [93] 0 0
Zabrze
Country [94] 0 0
Portugal
State/province [94] 0 0
Braga
Country [95] 0 0
Portugal
State/province [95] 0 0
Lisboa
Country [96] 0 0
Portugal
State/province [96] 0 0
Porto
Country [97] 0 0
Puerto Rico
State/province [97] 0 0
Guaynabo
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Krasnojarsk
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Leningrad
Country [100] 0 0
Russian Federation
State/province [100] 0 0
Moskovskaja Oblast
Country [101] 0 0
Russian Federation
State/province [101] 0 0
Sankt Petersburg
Country [102] 0 0
Russian Federation
State/province [102] 0 0
Sverdlovsk
Country [103] 0 0
Russian Federation
State/province [103] 0 0
Tatarstan
Country [104] 0 0
Russian Federation
State/province [104] 0 0
Tjumen
Country [105] 0 0
Russian Federation
State/province [105] 0 0
Kirov
Country [106] 0 0
Russian Federation
State/province [106] 0 0
Novosibirsk
Country [107] 0 0
Spain
State/province [107] 0 0
LA Coruña
Country [108] 0 0
Spain
State/province [108] 0 0
Lerida
Country [109] 0 0
Spain
State/province [109] 0 0
Madrid
Country [110] 0 0
Spain
State/province [110] 0 0
Pontevedra
Country [111] 0 0
Spain
State/province [111] 0 0
Barcelona
Country [112] 0 0
Spain
State/province [112] 0 0
Cadiz
Country [113] 0 0
Spain
State/province [113] 0 0
Malaga
Country [114] 0 0
Spain
State/province [114] 0 0
Sevilla
Country [115] 0 0
Switzerland
State/province [115] 0 0
Basel
Country [116] 0 0
Switzerland
State/province [116] 0 0
Bern
Country [117] 0 0
Turkey
State/province [117] 0 0
Ankara
Country [118] 0 0
Turkey
State/province [118] 0 0
Istanbul
Country [119] 0 0
Turkey
State/province [119] 0 0
Kocaeli
Country [120] 0 0
Turkey
State/province [120] 0 0
Mersin
Country [121] 0 0
Turkey
State/province [121] 0 0
Samsun
Country [122] 0 0
Turkey
State/province [122] 0 0
Trabzon
Country [123] 0 0
Turkey
State/province [123] 0 0
Van
Country [124] 0 0
Turkey
State/province [124] 0 0
Çankaya
Country [125] 0 0
Ukraine
State/province [125] 0 0
Chernihiv Governorate
Country [126] 0 0
Ukraine
State/province [126] 0 0
Crimean Regional Governmenta
Country [127] 0 0
Ukraine
State/province [127] 0 0
Kharkiv Governorate
Country [128] 0 0
Ukraine
State/province [128] 0 0
KIEV Governorate
Country [129] 0 0
Ukraine
State/province [129] 0 0
Podolia Governorate
Country [130] 0 0
Ukraine
State/province [130] 0 0
Ivano-Frankivsk
Country [131] 0 0
Ukraine
State/province [131] 0 0
Kharkov
Country [132] 0 0
Ukraine
State/province [132] 0 0
Lutsk
Country [133] 0 0
Ukraine
State/province [133] 0 0
Odesa
Country [134] 0 0
United Kingdom
State/province [134] 0 0
Glasgow
Country [135] 0 0
United Kingdom
State/province [135] 0 0
London
Country [136] 0 0
United Kingdom
State/province [136] 0 0
Nottingham
Country [137] 0 0
United Kingdom
State/province [137] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A study to evaluate the efficacy and safety of fenebrutinib on disability progression in
adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible
participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or
intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice
or web-based response system (IxRS). Approximately 946 participants will be enrolled and will
be recruited globally. Participants who discontinue study medication early or discontinue
from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a
positive benefit-risk result in the Primary Analysis of the study.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04544449
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04544449